AI Article Synopsis
- This study analyzed how demographic and clinical factors at baseline can predict the development of systemic lupus erythematosus (SLE) in patients with Sjögren's syndrome (SS).
- Researchers evaluated data from 1,082 SS patients over a median follow-up of about 3 years, finding that 4.5% developed SLE, with significant predictors identified including high disease activity scores and certain blood abnormalities.
- Key predictors for SLE development include shorter SS disease duration, higher disease activity (measured by ESSDAI), and specific serological markers, indicating a need for careful monitoring of patients with these risk factors.
Article Abstract
Objective: This study determined the impact of demographic factors, clinical manifestations, disease activity, and serological tests at baseline on future SLE development in Sjögren's syndrome (SS) patients.
Methods: This retrospective study assessed 1,082 SS patients without other autoimmune diseases at baseline who visited our hospital between January 2012 and March 2021. We analyzed demographic features, extra-glandular manifestations (EGMs), clinical indices, and laboratory values at baseline between the two groups divided per future SLE development (SS/SLE group vs SS group). The probability and predictors of SLE development in SS patients were estimated using the Kaplan-Meier method and Cox proportional hazards models.
Results: The median follow-up duration was 1083.5 days. Forty-nine patients (4.5%) developed SLE that met the 2012 Systemic Lupus International Collaborating Clinics or 2019 EULAR/ACR classification criteria. The baseline EULAR SS disease activity index (ESSDAI) score was significantly higher in the SS/SLE group ( < .001). The SS/SLE group had more lymphadenopathy and renal involvement ( = .015 and = .017, respectively). Shorter SS disease duration (<3 years) (hazard ratio [HR] = 2.12, = .0328), high ESSDAI (HR = 8.24, < .0001), leukopenia (HR = 4.17, = .0005), thrombocytopenia (HR = 3.38, = .0059), hypocomplementemia (HR = 29.06, <.0001), and positive for anti-dsDNA (HR = 13.70, < .0001), anti-ribonucleoprotein (RNP) (HR = 3.82, = .0027), and anti-ribosomal P (HR = 6.70, = .0002) at baseline were SLE development predictors in SS patients.
Conclusion: Shorter disease duration and higher disease activity of SS at baseline may be risk factors for future SLE development. Serologic predictors of SLE development are hypocomplementemia, leukopenia, thrombocytopenia, and positivity for anti-dsDNA, anti-RNP, and anti-ribosomal P antibodies. If the above factors are observed, close monitoring will be necessary during the follow-up period, considering the possibility of future SLE development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/09612033231204067 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Severe Lupus and Refractory Anemia.
Cureus
December 2024
Internal Medicine, Hospital da Senhora da Oliveira, Guimarães, PRT.
Systemic lupus erythematosus (SLE) is a multisystemic connective tissue disease with a wide range of clinical and laboratory manifestations. The diagnosis of SLE is often challenging due to the great variability in its presentation, and treatment should be individualized according to the patient's manifestations and affected organs. We present the clinical case of a 25-year-old female who developed SLE with severe hematological and renal involvement as first manifestations, including hemolytic anemia, thrombocytopenia, and nephrotic syndrome.
View Article and Find Full Text PDFComparative Analysis of CXCR5 Circulating DNA Methylation Levels in Autoimmune Rheumatic Diseases.
Immun Inflamm Dis
January 2025
Department of Rheumatology, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Objective: To assess CXC chemokine receptor 5 (CXCR5) circulating DNA methylation differences in autoimmune rheumatic diseases and their relation with clinical features.
Methods: Targeted methylation sequencing was performed using peripheral blood from 164 rheumatoid arthritis (RA), 30 systemic lupus erythematosus (SLE), 30 ankylosing spondylitis (AS), 30 psoriatic arthritis (PsA), 24 Sjögren's syndrome (SS) patients, and 30 healthy controls (HC).
Results: Significant differences in CXCR5 cg19599951 methylation were found between RA and HC, as well as AS and SLE.
Recent Insights Into Wnt-Related tRNA-Derived Fragments (tRFs) in Human Diseases.
J Cell Biochem
January 2025
Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
tRNA-derived fragments (tRFs) are a newly recognized class of small noncoding RNAs (sncRNAs) that play significant roles in various diseases. The Wnt pathway plays a key role in various physiological processes such as embryonic development, tissue renewal and regeneration. In the regulation of Wnt/β-catenin, Forkhead box k1(FOXK1), Frizzled class receptor 3 (FZD3), and Wnt5b can be targeted and inhibited by three tRFs: tRF3008A targets FOXK1 to inhibit colorectal cancer (CRC), 5'-tiRNAVal targets FZD3 to inhibit breast cancer (BrC), and tRF-22-8BWS7K092 targets Wnt5b to induce ferroptosis in lung cells.
View Article and Find Full Text PDFAn updated review on abnormal epigenetic modifications in the pathogenesis of systemic lupus erythematosus.
Front Immunol
January 2025
Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, China.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. The inconsistent prevalence of SLE between monozygotic twins suggests that environmental factors affect the occurrence of this disease. Abnormal epigenetic regulation is strongly associated with the pathogenesis of SLE.
View Article and Find Full Text PDFComprehensive treatment strategy in a patient with systemic lupus erythematosus-related pulmonary artery hypertension: a case report.
Eur Heart J Case Rep
January 2025
Division of Cardiology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa Ward, Tokyo 142-8555, Japan.
Background: Although the prognosis in systemic lupus erythematosus (SLE) has dramatically improved, pulmonary artery hypertension (PAH) is one of the life-threatening comorbidities associated with SLE. The management of the comorbidity is occasionally challenging due to the lack of consensus regarding treatment options including immunosuppressive agents, selective pulmonary vasodilators, and cardiac rehabilitation.
Case Summary: A 28-year-old female who terminated prednisolone after remission of SLE by her own discretion 3 years ago developed dyspnoea on effort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!